{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:10:18Z","timestamp":1793823018127,"version":"4.6.1"},"reference-count":22,"publisher":"Centers for Disease Control MMWR Office","issue":"35","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7435a1","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T14:34:13Z","timestamp":1758206053000},"page":"541-549","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis \u2014 United States, 2025"],"prefix":"10.15585","volume":"74","author":[{"given":"Rupa R.","family":"Patel","sequence":"first","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Hoover","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Lale","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Cabrales","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Byrd","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena P.","family":"Kourtis","sequence":"additional","affiliation":[{"name":"Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R1","unstructured":"CDC. HIV diagnoses, deaths, and prevalence: 2025 update. Atlanta, GA: US Department of Health and Human Services, CDC; 2025. https:\/\/www.cdc.gov\/hiv-data\/nhss\/hiv-diagnoses-deaths-and-prevalence-2025.html"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R2","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1016\/S2352-3018(25)00036-0","article-title":"Association of state-level PrEP coverage and new HIV diagnoses in the USA from 2012 to 2022: an ecological analysis of the population impact of PrEP.","volume":"12","author":"Sullivan","year":"2025","journal-title":"Lancet HIV"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R3","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/cid\/ciz1229","article-title":"Evidence of an association of increases in pre-exposure prophylaxis coverage with decreases in human immunodeficiency virus diagnosis rates in the United States, 2012\u20132016.","volume":"71","author":"Smith","year":"2020","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R4","doi-asserted-by":"publisher","first-page":"e5729","DOI":"10.1002\/pds.5729","article-title":"Adherence and persistence of HIV pre-exposure prophylaxis use in the United States.","volume":"33","author":"McCormick","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/cid\/ciaa037","article-title":"Persistence with human immunodeficiency virus pre-exposure prophylaxis in the United States, 2012\u20132017.","volume":"72","author":"Huang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R6","doi-asserted-by":"publisher","first-page":"e25252","DOI":"10.1002\/jia2.25252","article-title":"Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017.","volume":"22","author":"Coy","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women.","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R9","unstructured":"Food and Drug Administration. YEZTUGO (lenacapavir) tablets, for oral use; YEZTUGO (lenacapavir) injection, for subcutaneous use. Prescribing information. Silver Spring, MD: Food and Drug Administration; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/220020s000lbl.pdf"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women.","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R11","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons.","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R12","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2021. https:\/\/stacks.cdc.gov\/view\/cdc\/112360"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.su7101a1","article-title":"Standards required for the development of CDC evidence-based guidelines.","volume":"71","author":"Carande-Kulis","year":"2022","journal-title":"MMWR Suppl"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R15","unstructured":"Thomas J, Kneale D, McKenzie JE, Brennan SE, Bhaumik S. Determining the scope of the review and the questions it will address [Chapter 2]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds.\u00a0Cochrane handbook for systematic reviews of interventions. Version 6.5. Oxford, England: The Cochrane Collaboration; 2024. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-02"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R16","doi-asserted-by":"publisher","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction.","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R17","unstructured":"University of Liverpool. HIV drug interactions checker. Liverpool, United Kingdom; 2025. https:\/\/hiv-druginteractions.org\/checker"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R18","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC: US Department of Health and Human Services; 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Universal hepatitis B vaccination in adults aged 19\u201359 years: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R20","doi-asserted-by":"crossref","unstructured":"Terrault NA, Lok AS, McMahon BJ,  Update on prevention, diagnosis, and clinical management of chronic hepatitis B. Hepatol 2018;67:1546\u201359.29405329","DOI":"10.1002\/hep.29800"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R21","unstructured":"Gilead Sciences. HPTN103: PURPOSE 4. Foster City, CA: Gilead Sciences; 2025. https:\/\/www.purposestudies.com\/purpose4"},{"key":"key-10.15585\/mmwr.mm7435a1-202509181033-R22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJMe2408591","article-title":"The real PURPOSE of PrEP\u2014effectiveness, not efficacy.","volume":"391","author":"Walensky","year":"2024","journal-title":"N Engl J Med"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T14:34:16Z","timestamp":1758206056000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7435a1.htm?s_cid=mm7435a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":22,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2025,9,18]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7435a1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,18]]},"published":{"date-parts":[[2025,9,18]]}}}